• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Want to Know Why I'm Not Selling Moderna?

I'm staying long this name, and I'm staying long PFE and JNJ, and I'm staying long GILD and ABT. You know why? Because I'm optimistic.
By STEPHEN GUILFOYLE
May 07, 2020 | 11:00 AM EDT
Stocks quotes in this article: FB, CLX, GILD, PFE, JNJ, MRNA, ABT

"Operation Warp Speed". Haven't heard of it? That is just the Trump administration's program aimed at accelerating and supporting the effort to get a vaccine that targets the SARS-CoV-2 coronavirus that causes the disease known as Covid-19 to most Americans by the end of this year. Too fast? Too optimistic? Maybe. Maybe not.

What is optimism? Optimism is not what we all do every day. Watching the rising counts of both confirmed cases and the deaths that it has caused from near and far. Optimism is not being afraid to check Facebook (FB) just because you can't bear to see what friend is asking for prayers for a family member today.

Optimism is not staying home everyday, or is it heading out to work unsure of what you might bring home with you later... to your family. Optimism is not constantly hoping that maybe today, someone in the neighborhood found Clorox (CLX) wipes somewhere and sends a blast text as they had to with toilet paper and paper towels for months. Optimism is not having to worry about finding canned goods, or enough protein to feed a family on a regular basis.

Optimism

Optimism is the smartest scientists in the world working constantly toward finding solutions to a global problem, without regard for potential profit. There will be far less of that than you think. Optimism is people being called back to work. Think continuing claims should be higher, based on jobless claims. We all know many folks who have lost their jobs. Suddenly, I know a few who have been called back. Hmm.

Optimism is a llama in Belgium whose antibodies completely neutralize this coronavirus. True story. Optimism is the apparent efficacy of Gilead's (GILD) remdesivir, as not a cure, but a starting point, in treating the already ill. Optimism is the size and scale that firms such as Pfizer (PFE) and Johnson & Johnson (JNJ) can bring to the effort to find a vaccine, and then produce enough of it.

Optimism is also the news Moderna (MRNA) was able to announce on Thursday morning. Oh sure, Moderna reported first quarter financial performance on Thursday morning. Knocked the cover off of the ball? Hardly. The firm went to the tape with an EPS of -$0.35, beating expectations. Revenue? Just $8.39 million. Missed by a mile, down 47.7% year over year. Oh, did I mention the $483 million funding award from BARDA (Biomedical Advanced Research and Development Authority) to push an accelerated development of the mRNA-1273 vaccine candidate? Did I mention the collaborative effort agreed to with Lonza Ltd. to produce one billion doses of this vaccine per year?

Optimism is the FDA. The Food and Drug Administration approving this mRNA-1273 for Phase 2 clinical trials after that candidate had just entered into Phase 1 in March. This next phase begins imminently with 600 participants, and even as this phase just gets under way, plans are already being finalized the get a Phase 3 clinical trial (could hopefully be a last step) going by early this summer.

Effort

In a statement released by the firm, CEO Stephane Bancel said, "We are accelerating manufacturing scale-up and our partnership with Lonza puts us in a position to make and distribute as many vaccine doses of mRNA-1273 as possible, should it prove safe and effective." Bancel goes on to add that hopefully the firm could have the final product approved for 2021, and that Moderna as well as some of the other companies racing toward this objective are indeed set to ramp up production ahead of final approval. Bancel told CNBC on Thursday morning that he hoped the company could initiate the manufacture of this vaccine a soon as this July.

The Chart

Traders will quickly see the liberty I took in creating this Pitchfork. That liberty which was the omission of the late February spike and following selloff, as it appears to have been a news related algorithmic spasm and the chart works better without it. Hey, it's my money I'm working with here. Traders will also see that the shares are wrestling with the April highs this morning, so established resistance. Is it time to sell? Yes. It's been time technically. My target price was $44. Already a home run. I'm not selling. Screw that.

My Thoughts

I'm staying long this name, and I'm staying long Pfizer, and I'm staying long Johnson & Johnson, and I'm staying long Gilead, and I'm staying long Abbott Labs (ABT) . You know why? Because I'm optimistic. Because a group of older women just walked past my office window, trying to be socially distanced while still being friends. Because I have never heard the national anthem played since I was a boy and not shed a tear. Because I am rooting for the smartest people in the world working round the clock. Because I am rooting for everyone who has had to step up and also for everyone who has been afraid.

Simply put, I see victory and strength created through suffering. I hear the birds. I see the children. I feel the rise of a great nation, the greatest nation as it climbs off of the canvas. You see that flag over there, yeah that one... That flag is still there, Bucko. Rock on.

(Facebook, Clorox, Pfizer, Johnson & Johnson, and Abbott Labs are holdings in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells these stocks? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long MRNA, PFE, JNJ, GILD, CLX equity.

TAGS: Drug Approvals | Investing | Markets | Stocks | Technical Analysis | Trading | Biotechnology | Coronavirus

More from Investing

A Rally Driven by Fear (of Missing Out)

James "Rev Shark" DePorre
May 27, 2022 4:28 PM EDT

What's next after this seesaw week? One thing is for sure: More volatility.

Let's Take Nikola for a Spin. And Then Return It

Mark Sebastian
May 27, 2022 2:56 PM EDT

I wouldn't want to own NKLA, but I could see riding it for a few days.

In Awe of Marvell's Rally? Check the Charts, Not Your Emotions

Bruce Kamich
May 27, 2022 2:03 PM EDT

Here's why you should stay nimble as you approach MRVL after its post-earnings upswing.

Here's How to Wrangle JPMorgan, the '800-Pound Gorilla' of Banking

Brad Ginesin
May 27, 2022 1:27 PM EDT

The financial services giant just held its first investor day in three years -- let's open the vault and see what's inside.

As Zscaler Rallies, Charts Say the Stock Could Hit This Level Soon

Bruce Kamich
May 27, 2022 1:23 PM EDT

Here's how aggressive traders can play the cybersecurity name.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:58 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "The Tremendous Power of the Sell Button"
  • 02:46 PM EDT STEPHEN GUILFOYLE

    We're Shedding Some of This Holding on Strength

    Check out the Stocks Under $10 portfolio here!
  • 11:33 AM EDT PETER TCHIR

    Thoughts Ahead of the Fed Minutes

    Recent economic and earnings issues are convincing...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login